British pharmaceutical manufacturer GlaxoSmithKline has been fined £297m in relation to allegations of bribery in China.
A statement released by GSK said that, according to Chinese law, the company had “offered money or property to non-government personnel in order to obtain improper commercial gains, and been found guilty of bribing non-government personnel.” The guilty verdict, handed down in Changsha Intermediate People’s Court in Hunan Province, China, means the firm will pay…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
